chevron_leftBack
As of 24 April 2025, Enzo Biochem, Inc. has a market cap of $20.7M USD, ranking #29657 globally and #4345 in the United States. It ranks #2968 in the Healthcare sector, and #150 in the Diagnostics & Research industry.
Key Stats
Market Cap
$20.7MUSD
Enterprise Value
-$16.46MUSD
Revenue (TTM)
$29.09MUSD
EBITDA (TTM)
-$8.56MUSD
Net Income (TTM)
-$21.31MUSD
EBITDA Margin
-29%
Profit Margin
-73%
Company Profile
Country (HQ)
Sector
Healthcare
Industry
Diagnostics & Research
CEO
Kara Cannon
open_in_new
Employees
136
Founded
1976
Website
enzo.com
open_in_new
warningChart data may be delayed
| 1d | 1w | 1m | 3m | 6m | 1y |
|---|---|---|---|---|---|
| 1.3% | 4.8% | -18% | -39% | -66% | -63% |
Markets
| Exchange | Ticker | Price |
|---|---|---|
|
ENZB
Enzo Biochem Inc
ISIN: US2941001024
Shares Out.:
Shares Outstanding:
52.403M1
Shares Float:
37.752M2
TV:
TradingView:
SA:
Stock Analysis:
YF:
Yahoo Finance:
GF:
Google Finance:
BA:
Barron's:
MS:
Morningstar:
|
0.4000 USD |
1Market cap is calculated using shares outstanding.
2Float shares are publicly tradable shares, excluding insider-held stock.
About Enzo Biochem, Inc.
Enzo Biochem, Inc., a life sciences company, engages in the labeling and detection technologies from DNA to whole cell analysis in the United States and internationally. The company offers labels, dyes, antibodies, genomic probes, immunoassays, biochemicals, and proteins are used to label, detect, and visualize a biological target of interest in drug discovery exploration and drug development process development. Its proprietary products and technologies play roles in translational research and drug development areas, including cell biology, genomics, assays, immunohistochemistry, and small molecule chemistry. The company licenses its technology. It serves academic researchers, clinical researchers, biotechnology and pharmaceutical companies, and diagnostic manufacturers. Enzo Biochem, Inc. was incorporated in 1976 and is headquartered in Farmingdale, New York.
